Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Issue 1 (April 2015)

• Record Type: Journal Article
• Authors: De Grève, Jacques; Moran, Teresa; Graas, Marie-Pascale; Galdermans, Daniella; Vuylsteke, Peter; Canon, Jean-Luc; Schallier, Denis; Decoster, Lore; Teugels, Erik; Massey, Dan; Chand, Vikram K.; Vansteenkiste, Johan
• Is Part Of: Lung cancer. Volume 88:Issue 1(2015:Apr.)
• Page Start: 63
• Page End: 69
• Publication Date: 2015-04
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2015.01.013
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Afatinib monotherapy was active in NSCLC tumors with HER2 activating mutations.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Afatinib monotherapy was active in NSCLC tumors overexpressing wild-type EGFR.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Afatinib + paclitaxel was active in NSCLC patients after progression on afatinib.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Afatinib displayed a predictable and manageable safety profile.</p> </list-item> </list> </p> </sec> </abstract>